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| INTRODUCTION
Detection of lupus anticoagulant (LAC), as part of the laboratory criteria for classification of antiphospholipid syndrome (APS), is performed using dilute Russell's viper venom test (dRVVT) and activated partial thromboplastin time (APTT), being phospholipid-dependent functional clotting assays. [1] [2] [3] Interference of anticoagulants is a well-known issue in LAC testing and has been widely addressed in the literature, especially for vitamin K antagonists (VKAs) and direct oral anticoagulants (DOACs). [4] [5] [6] [7] [8] Unfractionated heparin (UFH), low-molecular-weight heparins (LMWHs), and heparinoids also carry the intrinsic potential of interfering with both APTT and dRVVT, as their anticoagulant activity mainly originates from catalyzation of the antithrombin-mediated inhibition of factors IIa and Xa. 9 Administration of LMWH and UFH to patients with APS is recommended in specific cases only, for example, as secondary thromboprophylaxis in patients with APS with recurrent venous thrombosis treated with VKA, in pregnant women with a history of obstetric APS, or as first-line treatment in catastrophic APS. 10 However, presence of heparins in samples admitted to the clinical laboratory for LAC testing is a common finding. 8, 11 The latter is often the result Therefore, the first aim of this study was to assess the effect of UFH, an LMWH (enoxaparin), and a heparinoid (danaparoid) on LAC assays over broad anti-Xa activity ranges and to establish their potential for causing false-positive results. In addition, it should be noted that many commercial reagents used for LAC detection already contain inhibitors that neutralize heparin effects up to specified anti-Xa activity levels. Recently, an interesting approach to overcome the influence of DOAC on coagulation assays has been introduced. This method, DOAC-Stop, is based on incubating plasma with an adsorbent material, consisting of activated carbon (AC), prior to further testing. 15 Several studies confirmed that this approach is able to remove DOAC from plasma. [16] [17] [18] [19] [20] [21] In this light, the second aim of our study was to evaluate whether AC is able to adsorb heparins and heparinoids and neutralize their effect on LAC assays. Starting from these solutions, working solutions at 20 anti-Xa IU/ mL were prepared in demineralized water for all 3 anticoagulants and added to NPP to obtain broad anti-Xa activity ranges. Anti-Xa activity measurement and LAC testing was performed in neat and spiked NPP as described below.
| MATERIALS AND METHODS

| Spiking experiment
Essentials
• Heparins/heparinoids may interfere with laboratory tests for lupus anticoagulant (LAC) detection.
• We evaluated effects of unfractionated heparin, enoxaparin, and danaparoid on LAC assays.
• False-positive LAC conclusions were obtained at supratherapeutic enoxaparin and danaparoid levels.
• Activated carbon was unable to eliminate the effects but prolonged the activated partial thromboplastin time clotting times.
| LAC testing and interpretation
According to current ISTH guidelines, 2 3-step LAC testing was carried out in a dRVVT-based and an APTT-based test system.
All tests were carried out on a STA-R Evolution analyzer ( 
| Anti-Xa activity measurement
Anti-Xa activity was measured using calibrated, chromogenic anti-Xa assays (STA-Liquid anti-Xa, Stago). For UFH and enoxaparin, STA-Multi Hep Calibrator plasma (Stago) was used. Biophen Orgaran calibration plasma (Hyphen BioMed, Neuville-sur-Oise, France) was used for danaparoid. All analyses were performed on STA analyzers (Stago).
| Sample pretreatment with AC
Norit Carbomix (Norit Pharmaceuticals, Klazienaveen, The Netherlands), an AC granulate intended for suspension in water and subsequent oral administration as reversal agent in acute intoxications, was used. This AC formulation allows homogenous and rapid suspension of AC in plasma samples. To determine the optimal AC concentration, increasing concentrations (0, 40, 80, and 120 mg/ mL) were added to NPP spiked with UFH (1.4 anti-Xa IU/mL), enoxaparin (1.5 anti-Xa IU/mL), and danaparoid (1.3 anti-Xa IU/mL). After addition of AC, samples were mixed for 5 minutes and centrifuged for 15 minutes at 2230 g. The supernatant was collected for further analysis. Anti-Xa activities were measured in all samples.
An AC concentration of 40 mg/mL was selected for further experiments. At multiple anti-Xa activity levels, aliquots of spiked NPP were pretreated with 40 mg/mL AC. Anti-Xa activity measurement, and LAC testing was performed on AC-treated and untreated plasmas.
| RESULTS AND DISCUSSION
| In vitro effect of UFH, enoxaparin, and danaparoid on lupus anticoagulant assays
| General findings
For UFH and enoxaparin, 12-point anti-Xa activity levels ranged from 0.1 to 3.0 IU/mL and from 0.2 to 2.9 IU/mL, respectively. Six-point anti-Xa activity levels for danaparoid ranged from 0.6 to 2.2 IU/mL. These broad activity ranges allowed to evaluate the impact of the tested anticoagulants on LAC assays from sub-to supratherapeutic levels. 9, 24, 25 In Figure 1 , dRVVT and APTT screening, mixing and confirmation results are depicted in function of measured anti-Xa activity in NPP spiked with UFH, enoxaparin, and danaparoid. It is clear that all 3 anticoagulants prolong both APTT and dRVVT results, with APTT being affected most. UFH exerted the highest effect on both assays, while the influence of enoxaparin and danaparoid was comparable. These general findings are in agreement with previous observations. 5, 7 Anti-Xa activity levels at which LAC test results exceeded the local cutoffs are summarized in Table 1 .
| APTT test system
Abnormal APTT screening and mixing results were obtained at the lowest anti-Xa activity levels (0.1, 0.2, and 0.6 anti-Xa IU/mL for UFH, enoxaparin, and danaparoid, respectively). It should be noted that the PTT-LA screen reagent used in these assays does not contain a heparin-neutralizing agent, which results, for example, in screening results outside the measurement range of the assay starting from 1.0 anti-Xa IU/mL UFH. The Staclot LA reagent used for APTT confirmation testing does contain a heparin inhibitor, with the manufacturer stating that heparin levels up to 1.0 anti-Xa IU/mL do not interfere with the assay. Indeed, abnormal results were obtained at high enoxaparin (starting from 2.5 anti-Xa IU/mL) and danaparoid (starting from 1.9 anti-Xa IU/mL) levels. Interestingly, prolongation of Staclot LA clotting times by UFH seems to be phospholipid dependent as high UFH levels (starting from 1.6 anti-Xa IU/mL) prolonged clotting times in the presence of hexagonal phase phospholipids to a higher extent than clotting times in the absence of phospholipids. This resulted in APTT confirmation results never exceeding the cutoff. Altogether, false-positive LAC conclusions in the APTT-based test system were obtained at supratherapeutic enoxaparin and danaparoid levels, starting from 2.5 and 1.9 anti-Xa IU/mL, respectively.
| dRVVT test system
As previously mentioned, dRVVT assays were less impacted com- The effects of UFH and enoxaparin on dRVVT tests seem to be independent from phospholipid content, as screen and confirm results were affected to a similar extent. This resulted in screen mix/confirm mix ratios never exceeding the cutoff. For danaparoid, abnormal ratios were seen from 1.9 anti-Xa IU/mL, although differences between obtained NCRs and cutoff values were within the assay's analytical variability and, therefore, seem to be less relevant. TA B L E 2 Dilute Russell's viper venom test screen and activated partial thromboplastin time screen clotting times measured in neat normal pooled plasma and normal pooled plasma spiked with unfractionated heparin, enoxaparin, and danaparoid at different anti-Xa activity levels before and after incubation of plasma with activated carbon APTT-based LAC conclusions at supratherapeutic anti-Xa activity levels starting from 2.5 and 1.9 anti-Xa IU/mL, respectively. 9, 24, 25 dRVVT screening and mixing tests were influenced as well, albeit at higher anti-Xa activity levels compared to APTT. Abnormal dRVVT confirmation tests and, consequently, false-positive dRVVT-based LAC conclusions were observed for danaparoid only, at high anti-Xa activity levels (from 1.9 anti-Xa IU/mL on). Anti-Xa activity levels at which false-positive LAC results were obtained exceeded those mentioned in the package inserts of the evaluated reagents up to where included inhibitors should neutralize heparin effects.
| Summary
| Impact of AC on anti-Xa activity and LAC assays
| AC concentration
Initial anti-Xa activities in untreated spiked NPP were 1.4, 1.5, and 1.3 anti-Xa IU/mL for UFH, enoxaparin, and danaparoid, respectively. Identical results were obtained for samples to which 40
and 80 mg/mL AC was added. When 120 mg/mL AC was added, slightly higher anti-Xa activities were measured (1.6, 1.7, and 1.4
anti-Xa IU/mL for UFH, enoxaparin, and danaparoid, respectively).
The latter may be attributed to incomplete removal of high AC concentrations after centrifugation and subsequent interference with the chromogenic anti-Xa assay or to adsorption of water by AC, resulting in increased anticoagulant plasma concentrations.
As there was no benefit from using higher AC concentrations, the lowest tested concentration (40 mg/mL) was selected for further experiments. AC concentrations <40 mg/mL were not tested, as it was previously described by others that lower AC concentrations, Table 2 ) performed on NPP were not affected by 40 mg/ mL AC, this AC concentration could be used safely. By using the same AC product as in our study, Frans et al 27 also showed that AC concentrations up to 80 mg/mL did not significantly interfere with routine clotting assays in neat plasma from healthy volunteers.
| Anti-Xa activity
Anti-Xa activity values for UFH, enoxaparin, and danaparoid obtained before and after incubating spiked NPP with AC (40 mg/mL) are shown in Figure 2 . Wilcoxon signed-rank tests revealed no significant differences between results before and after AC. These results indicate that AC does not adsorb the 3 tested anticoagulants from plasma. Similar findings were recently described by Exner et al 26 using DOAC-Stop. LA reagent containing HPE) was noticed as well, but differences were limited compared to screening tests (mean differences before and after AC for UFH and enoxaparin, respectively, 14.8 ± 6.9% and 3.2 ± 2.4% for mixing tests and 6.4 ± 6.4% and 2.9 ± 5.1% for confirmation tests). It should be noted that sample sizes are small and that the differences observed for PTT-LA screen were statistically insignificant based on Wilcoxon signed-rank tests. Moreover, these findings obtained using 1 type of AC and 1 APTT reagent probably may not be generalized for other AC products or APTT reagents. Although not explicitly mentioned by the authors, a similar pattern was seen in the study by Exner et al 26 for NPP spiked with enoxaparin and treated with DOAC-Stop. Prolongation of APTT results after applying DOAC-Stop was previously reported as well. 15, 16 Differences between APTT results for danaparoid and between dRVVT results for all 3 anticoagulants were limited and statistically insignificant. 
| LAC assays
| Summary
| CONCLUSIONS
Applying the 3-step procedure for LAC testing, including a screening, mixing, and confirmation step, avoids misclassification for LAC in the APTT test system caused by prolongation of APTT by UFH. For LMWH (enoxaparin) and danaparoid, false-positive LAC results in the APTT test system are observed, although at supratherapeutic anti-Xa activity levels. In the dRVVT test system, only false-positive LAC results for danaparoid were observed, again at high anti-Xa levels. In contrast to DOACs, heparins/heparinoids are not adsorbed by AC, and thus is not suited to avoid interference of heparin therapy in LAC testing.
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